Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Pharmaceutical TechnologyNovo Nordisk's Wegovy pill is already providing financial fuel in the company's bid to catch Eli Lilly.Metabolic & GLP-1Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) Pharmaceutical Technology Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Metabolic & GLP-1 Read full story Post navigation Previous: Angelini inks $4.1B Catalyst buy to enter US rare disease marketNext: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026